Trial: 202012001

A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma



Principal Investigator

Vij, Ravi

Disease Site

Acute Myeloid Leukemia (AML); Multiple Myeloma; Myeloid and Monocytic Leukemia

Learn more about this study at: